Symposium 12:Usefulness of continuous monitoring and infusers in type 2 diabetes mellitus
DOI:
https://doi.org/10.47196/diab.v56i3Sup.576Keywords:
continuous glucose monitoringAbstract
In recent years, the advent of new technologies such as continuous glucose monitoring (mcg) have had an impact on glycemic control and quality of life, providing a comprehensive view that provides much more data such as trends, glycemic variability, inadvertent hypoglycemia and patterns during sleep, prolonged fasting, physical activity and intercurrences. Even so, in people with type 2 diabetes, the evidence to recommend RT-CGM or Flash/IS-CGM was scarce, studies have been published, such as Mobile, Diamond and Optimize, exposing the benefit with achievement of lower HbA1c and hypoglycemia and longer Time in range. The strong evidence of association between TIR and coefficient of variation with cardiovascular disease and plaque vulnerability raises the importance of optimizing control in this population.
Current guidelines consider the indication of flash-type intermittent scanning mcg for adults with DM2 who receive multiple doses of daily insulin, poorly controlled, with recurrent hypoglycemia, impaired consciousness due to hypoglycemia, or disability that prevents capillary monitoring, advising scanning of at least 8 times a day.
References
I. Martens T, et al. Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial JAMA 2021;325(22):2262-2272.
II. Evans M, et al The impact of flash glucose monitoring on glycaemic control as measured by HbA1c: a meta-analysis of Clinical Trials and Real-World Observational Studies. Diabetes Ther 2020 Jan;11(1):83-95.
III. Beck RW, et al. Continuous glucose monitoring vs usual care in patients with type 2 diabetes receiving multiple daily Insulin injections: a randomized trial. Ann Intern Med 2017;167(6):365.374.
IV. Freckmann G. Insulin pump therapy for patients with type 2 diabetes mellitus: evidence, current barriers, and new technologies. Journal of Diab Scienc and Tech 2021; 15(4):901-915.
V. Bally L, et al. Fully closed-loop insulin delivery improves glucose control of inpatients with type 2 diabetes receiving hemodialysis. Kidney International 2019;96:593-596.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 on behalf of the authors. Reproduction rights: Argentine Diabetes Society
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
